RISK FACTORS FOR ACUTE MYOCARDIAL INFARCTION IN THE REPUBLIC OF SERBIA
Abstract
Background/Aim: Acute myocardial infarction (AMI) is a leading cause of morbidity and mortality from cardiovascular diseases (CVD) globally. The development of the disease is strongly associated with the presence and interaction of multiple risk factors – non-modifiable (sex, age, family history) and modifiable (hypertension, dyslipidemia, smoking, obesity, physical inactivity, diabetes mellitus, stress). The aim of this study is to analyze the prevalence of key risk factors for AMI among patients with acute coronary syndrome (ACS) treated in coronary care units in the Republic of Serbia (2006–2011), as well as in the general population of Serbia (2012–2022). Furthermore, these findings are compared with European and global averages to better understand the burden of risk factors and provide additional insight into the need for improved national preventive interventions.
Methods: A descriptive epidemiological study was conducted. Data on the prevalence of risk factors in hospitalized patients with acute coronary syndrome (ACS) for the period 2006–2011 were retrieved from the annual publications of the "Dr Milan Jovanović Batut" Institute of Public Health of Serbia – the National Registry for Acute Coronary Syndrome. The prevalence of the same risk factors in the general population of the Republic of Serbia for the period 2012–2022 was analyzed using national and international secondary data sources, including reports from the World Health Organization (WHO), the Global Adult Tobacco Survey (GATS), the Global Burden of Disease Study (GBD), the National Health Surveys from 2013 and 2019, and the European Health Interview Survey (EHIS). Risk factors were defined in accordance with the methodology of the data sources used and current international guidelines.
Results: A high prevalence of all analyzed risk factors was recorded among patients with ACS hospitalized in coronary care units in the Republic of Serbia. In 2011, approximately 35% of patients were recorded as smokers at the time of hospitalization (active smokers), about 73% had arterial hypertension, approximately 28% had diabetes mellitus, about 20% had obesity (BMI ≥30 kg/m²), and roughly 37% were physically inactive. More than half had dyslipidemia and a positive family history, while approximately 31% reported elevated psychosocial stress. Trend analysis for the 2012–2022 period indicates persistently high values of these modifiable risk factors in the general population, which match or exceed the levels recorded among hospitalized ACS patients in the preceding period.
Conclusion: The findings of this study indicate a persistently high prevalence of modifiable risk factors in the Republic of Serbia, which transitioned from the ACS patient population (2006–2011) to the general population over the following decade (2012–2022). These trends, which are more unfavorable than the European average, highlight the urgent need for integrated preventive strategies targeting modifiable risk factors to reduce the overall cardiovascular burden in the Republic of Serbia.
References
World Health Organization. Cardiovascular diseases (CVDs) [Internet]. Geneva: World Health Organization; 2025 [cited 2025 Dec 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi:10.1093/eurheartj/ehz425.
Vasiljević Z. Akutni koronarni sindrom: patofiziološki mehanizam, klasifikacija i klinički oblici. Acta Clin. 2006; 6(1):29–36.
Grech ED, Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ. 2003; 326:259–261.
Institute for Health Metrics and Evaluation. Global Burden of Disease Results Tool [Internet]. Seattle: IHME; 2023 [cited 2025 Dec 25]. Available from: https://vizhub.healthdata.org
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2016;23(11):NP1–NP96.
Lloyd-Jones DM, Nam BH, D’Agostino RB Sr, Levy D, Murabito JM, Wang TJ, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA. 2004; 291:2204–2211.
World Health Organization. Global Health Observatory (GHO) data repository [Internet]. Geneva: World Health Organization; 2022 [cited 2025 Dec 25]. Available from: https://www.who.int/data/gho
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1):111–188. doi:10.1093/eurheartj/ehz455.
Institute of Public Health of Serbia “Dr Milan Jovanović Batut”. National Health Survey Serbia 2022. Belgrade: Institute of Public Health of Serbia “Dr Milan Jovanović Batut”; 2023.
Ministry of Health of the Republic of Serbia. National Health Surveys of the Republic of Serbia 2013 and 2019. Belgrade: Ministry of Health of the Republic of Serbia; 2019.
Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364:953–962.
O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376:112–123.
Global Adult Tobacco Survey (GATS). Serbia country report [Internet]. Geneva: World Health Organization; [cited 2025 Dec 25]. Available from: https://www.who.int/teams/noncommunicable-diseases/surveillance
OECD, European Union. Health at a Glance: Europe 2022 [Internet]. Paris: OECD Publishing; 2022 [cited 2025 Dec 25]. Available from: https://www.oecd.org/health/health-at-a-glance-europe/
Institute of Public Health of Serbia “Dr Milan Jovanović Batut”. Registry for Acute Coronary Syndrome [Internet]. Belgrade: Institute of Public Health of Serbia “Dr Milan Jovanović Batut”; 2006–2011 [cited 2025 Dec 25]. Available from: https://www.batut.org.rs
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14):1289–1367.
Institute of Public Health of Serbia “Dr Milan Jovanović Batut”. Results of the National Health Survey of the Republic of Serbia 2013. Belgrade: Institute of Public Health of Serbia “Dr Milan Jovanović Batut”; 2014.
Statistical Office of the Republic of Serbia; Institute of Public Health of Serbia “Dr Milan Jovanović Batut”. National Health Survey of the Republic of Serbia 2019. Belgrade: Statistical Office of the Republic of Serbia; 2020.
Institute for Health Metrics and Evaluation. GBD country profile: Serbia [Internet]. Seattle: IHME; 2023 [cited 2025 Dec 25]. Available from: https://vizhub.healthdata.org
European Health Interview Survey (EHIS). Methodology and indicators [Internet]. Luxembourg: Eurostat; [cited 2025 Dec 25]. Available from: https://ec.europa.eu/eurostat
World Health Organization. Obesity [Internet]. Geneva: World Health Organization; [cited 2025 Dec 25]. Available from: https://www.who.int/health-topics/obesity
World Health Organization. Obesity and overweight [Internet]. Geneva: World Health Organization; 2025 [cited 2025 Dec 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1223–1249. doi:10.1016/S0140-6736(20)30752-2.
Timmis A, Vardas P, Townsend N, Torbica A, Kallikazaros I, Leszek P, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022; 43(8):716–799. doi:10.1093/eurheartj/ehab892.
World Health Organization. WHO report on the global tobacco epidemic, 2023. Geneva: WHO; 2023.
World Health Organization. Global action plan on physical activity 2018–2030: More active people for a healthier world. Geneva: WHO; 2018.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227–3337. doi:10.1093/eurheartj/ehab484.
GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021; 397(10292):2337–2360. doi:10.1016/S0140-6736(21)01169-7.
GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017; 377(1):13–27. doi:10.1056/NEJMoa1614362.
Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1·9 million participants. Lancet Glob Health. 2018; 6(10):e1077–e1086. doi:10.1016/S2214-109X(18)30357-7.
D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile. Circulation. 2008; 117:743–753.
Hackshaw A, Morris JK, Boniface S, Tang JL, Milenković D. Low cigarette consumption and risk of coronary heart disease and stroke. BMJ. 2018; 360:j5855.
Williams B, Mancia G, Spiering W, Azizi M, Burnier M, Clement DL, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33):3021–3104.
Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, et al. Diabetes and vascular disease: a meta-analysis of individual participant data. N Engl J Med. 2014; 371:1980–1992.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins and cardiovascular risk. Eur Heart J. 2017; 38:2459–2472.
Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe. Eur Heart J. 2003; 24:987–1003.
Steptoe A, Kivimäki M. Stress and cardiovascular disease. Annu Rev Public Health. 2013; 34:337–354.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease. Circulation. 1998; 97:1837–1847.
World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013–2020 [Internet]. Geneva: World Health Organization; 2013 [cited 2025 Dec 25]. Available from: https://www.who.int/publications/i/item/9789241506236
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39(2):119–177. doi:10.1093/eurheartj/ehx393.
Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016; 1:CD001800. doi:10.1002/14651858.CD001800.pub3.
Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation. 2011; 124(22):2458–2473. doi:10.1161/CIR.0b013e318235eb4d.
Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet. 2004; 364(9438):937–952.
Critchley JA, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004; (1):CD003041.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387:957–967.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385:1397–1405.